Skip to main content
SpringerLink
Log in

ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500mg/m2 and carboplatin 800mg/m2 (CTCb) followed by stem cell transplantation.

Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pretransplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning.

Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview posttransplant. One patient was lost to follow-up and two patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment.

In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.J Clin Oncol 1992;10: 1743–1747.

    Article  CAS  PubMed  Google Scholar 

  2. Peters WPet al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.J Clin Oncol 1988;16: 1368–1376.

    Article  Google Scholar 

  3. Kennedy MJet al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following doseintense induction as initial therapy for metastatic breast cancer.J Natl Cancer Inst 1991;83: 920–926.

    Article  CAS  PubMed  Google Scholar 

  4. Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoeitic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.Bone Marrow Transplant 1994;13: 619–624.

    CAS  PubMed  Google Scholar 

  5. Dunphy FRet al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.Cancer 1994;73: 2157–2167.

    Article  CAS  PubMed  Google Scholar 

  6. Weaver CHet al. Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers.Bone Marrow Transplant 1997;19: 671–678.

    Article  CAS  PubMed  Google Scholar 

  7. Wagstaff AJ, Ward A, Benfield P and Heel RC. Carboplatin: a preliminary review of its pharmacodynamic and pharmokinetic properties and therapeutic efficacy in the treatment of cancer.Drugs 1989;327: 162–190.

    Article  Google Scholar 

  8. Swenerton Ket al. Cisplatin-Cyclophosphamide versus Carboplatin-Cyclophosphamide in advanced ovarian cancer: a randomized Phase III study of the National Cancer Institute of Canada clinical trials group.J Clin Oncol 1992;10: 718–726.

    Article  CAS  PubMed  Google Scholar 

  9. Alberts DSet al. Improved therapeutic index of Carboplatin plus Cyclophosphamide versus Cisplatin plus Cyclophosphamide: Final report by the Soutwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.J Clin Oncol 1992;10: 706–717.

    Article  CAS  PubMed  Google Scholar 

  10. Meyers FJ, Welborn J, Lewis JP, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses.J Clin Oncol 1989;7: 173–178.

    Article  CAS  PubMed  Google Scholar 

  11. Vogler WRet al. Phase II clinical trial of carboplatin in relapsed and refractory leukemia.Leukemia 1992;6: 1072–1075.

    CAS  PubMed  Google Scholar 

  12. Fields KKet al. Two novel high-dose treatment regimens for metastatic breast cancer-Ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.Semin Oncol 1993;20(5 Suppl 6): 59–66.

    CAS  PubMed  Google Scholar 

  13. Parsons SKet al. Severe ototoxicity following carboplatin containing conditioning regimen for autologous marrow transplantation for neuroblastoma.Bone Marrow Transplant 1998;22: 669–674.

    Article  CAS  PubMed  Google Scholar 

  14. Namouni Fet al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a hematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study.Eur J Cancer 1997;33: 2368–2375.

    Article  CAS  PubMed  Google Scholar 

  15. Freilich RJet al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.Med Pediat Oncol 1996;26: 95–100.

    Article  CAS  Google Scholar 

  16. Broun REet al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.Cancer 1997;79: 1605–1610.

    Article  CAS  PubMed  Google Scholar 

  17. Beyer Jet al. Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.Cancer 1997;79: 161–168.

    Article  CAS  PubMed  Google Scholar 

  18. Shea TCet al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.J Clin Oncol 1989;7: 651–666.

    Article  CAS  PubMed  Google Scholar 

  19. Kimberley BP, Brown DK, Allen JB. Distortion product emissions and sensorineural hearing loss. In: Robinette MS, Glattke TJ (eds).Otoaccoustic Emissions: Clinical Applications. Thieme: New York, 1997, pp 181–204.

    Google Scholar 

  20. Schell MJet al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation.J Clin Oncol 1989;7: 754–760.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Seetion of Hematology and Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, 30912, Augusta, GA, USA

    AP Jillella, AM Kallab & K Harkness

  2. Department of Audiology and Speech Pathology, Medical College of Georgia, 1120 15th Street, BAA 5407, 30912, Augusta, GA, USA

    GW Britt & GD Garner

  3. Office of Biostastics Medical College of Georgia, 1120 15th Street, BAA 5407, 30912, Augusta, GA, USA

    MS Litaker

Authors
  1. AP Jillella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. GW Britt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MS Litaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. AM Kallab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Harkness
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. GD Garner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to AP Jillella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jillella, A., Britt, G., Litaker, M. et al. ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer. Med Oncol 17, 287–292 (2000). https://doi.org/10.1007/BF02782193

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02782193

Keywords

Search

Navigation